A Philadelphia health IT company with software aimed at helping oncology patients decide more suitable, personalized cancer treatments has changed its name to reflect the decision-making platform it began marketing last year and to aid its national expansion.
Eviti, formerly known as ITA Partners, started as a case manager for cancer treatment 10 years ago, but has evolved into a health IT company. Its clinical-decision, web-based software, eviti, aggregates data on cancer types, proven cancer treatment options and clinical profiles to provide more personalized treatment options and reduce inefficiencies and costs.
The software is aimed at payers and physicians in their conversations with patients and is being pushed out to nurse case managers. A patient portal will be developed in the future, Susan Spalding, a spokeswoman for the company, told MedCity News in a phone interview.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Forty percent of the time there’s some element of a cancer treatment that does not meet acceptable standards, said Spalding. “We were often receiving referrals after the cancer treatment had already started because most payer organizations don’t require the treatment to be pre-certified — [the treatment] could start whether the provider would pay for it or not. ”
The company launched the eviti software program in October 2009 and it became commercially available in October last year. An app for the software is also being developed, Spalding said.
“Our customers have come to associate eviti with quality oncology treatment intelligence,” said Eduardo Beruff, CEO of eviti in a statement. “This name change reflects eviti’s growing national prominence as evidenced by the 4,200 oncologists already registered to use the eviti platform.”
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
